𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: Results from the CHARM trial

✍ Scribed by David T. Rubin; Parvez Mulani; Jingdong Chao; Paul F. Pollack; Arielle G. Bensimon; Andrew P. Yu; Subrata Ghosh


Book ID
112101174
Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
788 KB
Volume
18
Category
Article
ISSN
1078-0998

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Adalimumab safety in global clinical tri
✍ Jean-FrΓ©dΓ©ric Colombel; William J. Sandborn; Remo Panaccione; Anne M. Robinson; πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 145 KB πŸ‘ 2 views

Background: Adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, is approved for the treatment of Crohn's disease (CD) in adults. We evaluated the overall safety profile of adalimumab in global clinical trials in patients with CD. Patients who participated in these tr